Trial · NCT03442764
A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)
NCT03442764, Phase 2, Completed, MyoKardia, Inc.; results first posted 2022-08-09
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM). Trials, record NCT03442764. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03442764
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)
- NCT number
- NCT03442764
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 59 participants, actual
- Lead sponsor
- MyoKardia, Inc.
- Conditions
- Non-obstructive Hypertrophic Cardiomyopathy
- Interventions
- mavacamten, Placebo
- First posted
- 2018-02-22
- Last updated
- 2022-08-09
- Results first posted
- 2022-08-09
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of Participants Who Experienced at Least One Treatment Emergent Adverse Event (TEAE) | From first dose to 8 weeks following last dose (Up to 24 weeks) | This is the percentage of participants who experienced at least one treatment emergent adverse event (TEAE) |
| Primary | Percentage of Participants Who Experienced at Least One Serious Treatment-emergent Adverse Event (STEAE) | From first dose to 8 weeks following last dose (Up to 24 weeks) | This is the percentage of participants who experienced at least one serious treatment-emergent adverse event (STEAE) |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percentage of Participants Who Experienced at Least One Treatment Emergent Adverse Event (TEAE) | From first dose to 8 weeks following last dose (Up to 24 weeks) | All treated participants | percentage of participants | NUMBER |
| PRIMARY | Percentage of Participants Who Experienced at Least One Serious Treatment-emergent Adverse Event (STEAE) | From first dose to 8 weeks following last dose (Up to 24 weeks) | All treated participants | percentage of participants | NUMBER |
Source ClinicalTrials.gov
Results by group6
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants Who Experienced at Least One Treatment Emergent Adverse Event (TEAE) | Group 1 | 88.9 | percentage of participants | ||
| Percentage of Participants Who Experienced at Least One Treatment Emergent Adverse Event (TEAE) | Group 2 | 90.5 | percentage of participants | ||
| Percentage of Participants Who Experienced at Least One Treatment Emergent Adverse Event (TEAE) | Placebo | 68.4 | percentage of participants | ||
| Percentage of Participants Who Experienced at Least One Serious Treatment-emergent Adverse Event (STEAE) | Group 1 | 11.1 | percentage of participants | ||
| Percentage of Participants Who Experienced at Least One Serious Treatment-emergent Adverse Event (STEAE) | Group 2 | 9.5 | percentage of participants | ||
| Percentage of Participants Who Experienced at Least One Serious Treatment-emergent Adverse Event (STEAE) | Placebo | 21.1 | percentage of participants |
Source ClinicalTrials.gov
Participant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Group 1 | 19 | |
| Overall Study | STARTED | Group 2 | 21 | |
| Overall Study | STARTED | Placebo | 19 | |
| Overall Study | COMPLETED | Group 1 | 18 | |
| Overall Study | COMPLETED | Group 2 | 21 | |
| Overall Study | COMPLETED | Placebo | 19 | |
| Overall Study | NOT COMPLETED | Group 1 | 1 | |
| Overall Study | NOT COMPLETED | Group 2 | 0 | |
| Overall Study | NOT COMPLETED | Placebo | 0 |
Source ClinicalTrials.gov
Adverse events320
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Palpitations | Cardiac disorders | Group 1 Mavacamten | 1 | 18 | |
| other | Palpitations | Cardiac disorders | Group 2 Mavacamten | 5 | 21 | |
| other | Palpitations | Cardiac disorders | Combined MAVA Treatment Group (Group 1+ Group 2) | 6 | 39 | |
| other | Palpitations | Cardiac disorders | Placebo | 3 | 19 | |
| other | Atrial fibrillation | Cardiac disorders | Group 1 Mavacamten | 0 | 18 | |
| other | Atrial fibrillation | Cardiac disorders | Group 2 Mavacamten | 2 | 21 | |
| other | Atrial fibrillation | Cardiac disorders | Combined MAVA Treatment Group (Group 1+ Group 2) | 2 | 39 | |
| other | Atrial fibrillation | Cardiac disorders | Placebo | 0 | 19 | |
| other | Cardiac Failure | Cardiac disorders | Group 1 Mavacamten | 1 | 18 | |
| other | Cardiac Failure | Cardiac disorders | Group 2 Mavacamten | 1 | 21 |
1 to 10 of 320Source ClinicalTrials.gov
See all 320 adverse eventsAdverse event totals12
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Group 1 Mavacamten | 0 | 18 |
| Total, all-cause mortality | Group 2 Mavacamten | 0 | 21 |
| Total, all-cause mortality | Combined MAVA Treatment Group (Group 1+ Group 2) | 0 | 39 |
| Total, all-cause mortality | Placebo | 0 | 19 |
| Total, other adverse events | Group 1 Mavacamten | 16 | 18 |
| Total, other adverse events | Group 2 Mavacamten | 18 | 21 |
| Total, other adverse events | Combined MAVA Treatment Group (Group 1+ Group 2) | 34 | 39 |
| Total, other adverse events | Placebo | 11 | 19 |
| Total, serious adverse events | Group 1 Mavacamten | 2 | 18 |
| Total, serious adverse events | Group 2 Mavacamten | 2 | 21 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 adverse event totalsPapers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 32466879 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03442764
GET https://conductscience.org/api/trials/v1/NCT03442764/events?page=2